Perrigo Company plc (NYSE:PRGO) Shares Purchased by SG Americas Securities LLC

SG Americas Securities LLC increased its stake in Perrigo Company plc (NYSE:PRGO - Free Report) by 152.9% in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 67,947 shares of the company's stock after acquiring an additional 41,079 shares during the quarter. SG Americas Securities LLC's holdings in Perrigo were worth $1,905,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Cedar Wealth Management LLC raised its position in shares of Perrigo by 2.1% during the 4th quarter. Cedar Wealth Management LLC now owns 21,966 shares of the company's stock worth $565,000 after purchasing an additional 450 shares during the last quarter. Amalgamated Bank raised its holdings in shares of Perrigo by 0.8% during the fourth quarter. Amalgamated Bank now owns 64,086 shares of the company's stock valued at $1,648,000 after acquiring an additional 522 shares during the last quarter. Fox Run Management L.L.C. lifted its position in shares of Perrigo by 5.1% in the fourth quarter. Fox Run Management L.L.C. now owns 11,381 shares of the company's stock valued at $293,000 after acquiring an additional 548 shares in the last quarter. Snowden Capital Advisors LLC increased its position in shares of Perrigo by 3.6% during the fourth quarter. Snowden Capital Advisors LLC now owns 24,337 shares of the company's stock worth $626,000 after purchasing an additional 842 shares in the last quarter. Finally, Legacy Wealth Asset Management LLC raised its stake in Perrigo by 5.6% in the 1st quarter. Legacy Wealth Asset Management LLC now owns 18,302 shares of the company's stock valued at $513,000 after purchasing an additional 978 shares during the last quarter. 95.91% of the stock is currently owned by institutional investors and hedge funds.

Perrigo Trading Up 0.2%

Shares of PRGO traded up $0.07 during midday trading on Thursday, reaching $26.34. The company had a trading volume of 911,929 shares, compared to its average volume of 1,474,272. Perrigo Company plc has a 1-year low of $23.14 and a 1-year high of $30.93. The company has a quick ratio of 1.28, a current ratio of 2.36 and a debt-to-equity ratio of 0.82. The firm has a 50 day simple moving average of $26.09 and a 200-day simple moving average of $26.10. The stock has a market cap of $3.62 billion, a PE ratio of -20.10 and a beta of 0.46.

Perrigo (NYSE:PRGO - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported $0.60 EPS for the quarter, topping analysts' consensus estimates of $0.56 by $0.04. Perrigo had a negative net margin of 4.16% and a positive return on equity of 8.93%. The company had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1.09 billion. During the same period in the previous year, the firm earned $0.29 earnings per share. Perrigo's quarterly revenue was down 3.5% compared to the same quarter last year. Research analysts forecast that Perrigo Company plc will post 2.56 EPS for the current fiscal year.

Perrigo Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 17th. Investors of record on Friday, May 30th were given a dividend of $0.29 per share. This represents a $1.16 dividend on an annualized basis and a dividend yield of 4.40%. The ex-dividend date was Friday, May 30th. Perrigo's payout ratio is -88.55%.

Wall Street Analyst Weigh In

Separately, Wall Street Zen upgraded shares of Perrigo from a "hold" rating to a "buy" rating in a research report on Saturday, May 24th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $33.00.

Perrigo Company Profile

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.